All News

Found 83 articles

• Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in Miami, FL. Please see additional details below.

• Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

  5/16/2022

  Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, reported financial results for the first quarter ended March 31, 2022 and summarized recent business highlights.

• Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

  5/3/2022

  Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, announced that the RECOVER study is progressing well and all sites in the United States have been initiated.

• Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

  4/26/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that it will host a key opinion leader webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders on Tuesday, May 3, 2022 at 10:00am Eastern Time.

• Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference

  3/22/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat and one-on-one investor meetings at the Maxim Virtual Growth Conference, to be held March 28-30, 2022.

• Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

  3/18/2022

  Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in March and invites investors to participate in virtual one-on-one meetings.

• Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

  3/15/2022

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), today reported financial results for the full year ended December 31, 2021 and summarized recent business highlights.

• Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

  2/1/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that the first patients have been dosed in a pivotal Phase 3 study and long-term safety trial to assess Reviva’s new chemical entity brilaroxazine for the treatment of subjects with an acute exacerbation of schizophrenia.

• 

  Clinical Catch-Up: January 10-14

  1/17/2022

  Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.

• Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

  1/10/2022

  Reviva Pharmaceuticals Holdings, Inc. announced the U.S. Food and Drug Administration has notified the Company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia.

• Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

  12/20/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings.

• Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights

  11/15/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today reported financial results for the third quarter of 2021 and summarized recent business highlights.

• Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Conference

  9/15/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Benzinga Healthcare Small Cap Conference.

• Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/2/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

• Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights

  8/16/2021

  Reviva Pharmaceuticals Holdings, Inc. today reported financial results for the second quarter of 2021 and summarized recent business highlights.

• Reviva Added to Russell Microcap® Index

  6/28/2021

  Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, announced it has joined the broad-market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution.

• Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering

  5/27/2021

  Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, announced the pricing of its upsized underwritten public offering of 8,000,000 shares of its common stock and accompanying investor warrants to purchase up to 6,000,000 shares of common stock.

• 

  Clinical Catch-Up: April 26-30

  5/3/2021

  Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.

• Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

  4/26/2021

  Met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder

• Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update

  3/22/2021

  -Closed Merger with Tenzing Acquisition Corp and publicly listed on  NASDAQ Capital Market - -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved-